| scholarly article | Q13442814 |
| P50 | author | Ju-Won Roh | Q52588979 |
| Koji Matsuo | Q61864013 | ||
| Anil K. Sood | Q88114757 | ||
| Masato Nishimura | Q114188749 | ||
| P2093 | author name string | Jie Huang | |
| Gabriel Lopez-Berestein | |||
| Nicholas B Jennings | |||
| Wei Hu | |||
| Sun Joo Lee | |||
| Alpa M Nick | |||
| Rebecca L Stone | |||
| Chunhua Lu | |||
| Robert L Coleman | |||
| Robert B Jaffe | |||
| Michael T Deavers | |||
| Robert R Langley | |||
| Mian M K Shahzad | |||
| Edna Mora | |||
| Blake W Goodman | |||
| De-yu Shen | |||
| Han Hee Dong | |||
| P2860 | cites work | Modes of resistance to anti-angiogenic therapy | Q24608005 |
| Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma | Q28288817 | ||
| Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene | Q29547732 | ||
| Tumor angiogenesis | Q29614938 | ||
| Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid | Q29617640 | ||
| What Is the Evidence That Tumors Are Angiogenesis Dependent? | Q29620029 | ||
| Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma. | Q33638230 | ||
| Regulation of tumor angiogenesis by EZH2. | Q34073170 | ||
| Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer | Q34558061 | ||
| Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion | Q35103303 | ||
| Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells | Q35131712 | ||
| Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. | Q36583521 | ||
| EphA2 overexpression is associated with angiogenesis in ovarian cancer | Q36677168 | ||
| Experience with bevacizumab in the management of epithelial ovarian cancer | Q36873062 | ||
| Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? | Q36932941 | ||
| Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis | Q37120111 | ||
| VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis | Q37283444 | ||
| Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies | Q37307140 | ||
| Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications | Q37410402 | ||
| PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment | Q39901011 | ||
| Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. | Q40100311 | ||
| Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis | Q40191493 | ||
| Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma | Q40252227 | ||
| Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. | Q40642966 | ||
| Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer | Q42000250 | ||
| Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. | Q51792931 | ||
| Vascular endothelial growth factor expression in early stage ovarian carcinoma | Q53359012 | ||
| Antiangiogenic therapy for cancer: an update | Q79938432 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| ovarian cancer | Q172341 | ||
| P304 | page(s) | 6030-6039 | |
| P577 | publication date | 2011-07-27 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer | |
| P478 | volume | 71 |
| Q38387402 | A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia |
| Q36793431 | ATP11B mediates platinum resistance in ovarian cancer |
| Q97524272 | Aberrant promoter methylation of NOTCH1 and NOTCH3 and its association with cervical cancer risk factors in North Indian population |
| Q38553247 | An overview of early investigational therapies for chemoresistant ovarian cancer. |
| Q35205410 | Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. |
| Q37654522 | Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. |
| Q46083075 | Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. |
| Q48715887 | Chitosan Nanoparticles for miRNA Delivery |
| Q36471117 | Controlling fibrous capsule formation through long-term down-regulation of collagen type I (COL1A1) expression by nanofiber-mediated siRNA gene silencing. |
| Q40346499 | DLL4 as a predictor of pelvic lymph node metastasis and a novel prognostic biomarker in patients with early-stage cervical cancer |
| Q89615461 | Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial |
| Q36971300 | Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth |
| Q35418092 | Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts |
| Q53454303 | Expression of delta-like 4 (Drosophila) and vascular endothelial growth factor A in colon cancer and association with tumour angiogenesis. |
| Q40236299 | Expressions of OCT4, Notch1 and DLL4 and their clinical implications in epithelial ovarian cancer |
| Q40779503 | HDAC5 promotes colorectal cancer cell proliferation by up-regulating DLL4 expression |
| Q94562195 | Heritable modifiers of the tumor microenvironment influence nanoparticle uptake, distribution and response to photothermal therapy |
| Q91756542 | High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer |
| Q37050459 | Influence of up-regulation of Notch ligand DLL4 on biological behaviors of human gastric cancer cells |
| Q36905854 | Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis |
| Q40440350 | Jagged1 and DLL4 expressions in benign and malignant pancreatic lesions and their clinicopathological significance |
| Q38267262 | Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer |
| Q92669024 | NOTCH2/NOTCH3/DLL3/MAML1/ADAM17 signaling network is associated with ovarian cancer |
| Q37958937 | New pathways and mechanisms regulating and responding to Delta-like ligand 4-Notch signalling in tumour angiogenesis |
| Q35928220 | New ways to successfully target tumor vasculature in ovarian cancer |
| Q34491211 | Notch signaling in serous ovarian cancer |
| Q39173323 | Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells. |
| Q38937915 | Notch: A multi-functional integrating system of microenvironmental signals |
| Q33728010 | PET Imaging of Dll4 Expression in Glioblastoma and Colorectal Cancer Xenografts Using (64)Cu-Labeled Monoclonal Antibody 61B |
| Q33721304 | Retracted: Clinical Impact of De-Regulated Notch-1 and Notch-3 in the Development and Progression of HPV-Associated Different Histological Subtypes of Precancerous and Cancerous Lesions of Human Uterine Cervix |
| Q38174045 | Role of Notch signalling pathway in cancer and its association with DNA methylation |
| Q85579065 | State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer |
| Q38435424 | Targeting Tumor Initiating Cells through Inhibition of Cancer Testis Antigens and Notch Signaling: A Hypothesis |
| Q37696748 | Targeting notch signaling pathway in cancer: clinical development advances and challenges |
| Q37601970 | The Notch ligand Delta-like 4 (DLL4) as a target in angiogenesis-based cancer therapy? |
| Q95642052 | The Role of DLLs in Cancer: A Novel Therapeutic Target |
| Q41141631 | The Vascular Notch Ligands Delta-Like Ligand 4 (DLL4) and Jagged1 (JAG1) Have Opposing Correlations with Microvascularization but a Uniform Prognostic Effect in Primary Glioblastoma: A Preliminary Study |
| Q48521375 | The presence of VEGF and Notch2 during preantral-antral follicular transition in infantile rats: Anatomical evidence and its implications |
| Q38747422 | The role of Notch signaling in the mammalian ovary |
| Q37694018 | The role of Notch signalling in ovarian angiogenesis. |
| Q47134647 | Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies |
| Q26781924 | Tissue Factor-Factor VII Complex As a Key Regulator of Ovarian Cancer Phenotypes |
| Q38133568 | Understanding and targeting resistance to anti-angiogenic therapies |
| Q39036896 | Zebrafish phenotypic screen identifies novel Notch antagonists. |
| Q36848635 | β -Elemene-Attenuated Tumor Angiogenesis by Targeting Notch-1 in Gastric Cancer Stem-Like Cells |
Search more.